The present disclosure provides an agent that contains a substance which inhibits signaling from CXCL5 and that is for suppressing tissue stem cell aging.
A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
C12N 5/02 - Propagation of single cells or cells in suspensionMaintenance thereofCulture media therefor
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
FUSO PHARMACEUTICAL INDUSTRIES, LTD. (Japan)
Inventor
Kawabata, Atsufumi
Sekiguchi, Fumiko
Toyooka, Naoki
Okada, Takuya
Nishikawa, Hiroyuki
Abstract
The present invention provides a compound of formula (I):
The present invention provides a compound of formula (I):
wherein R1, R2, R3, R4, k, l, m and n are as defined in the specification,
or a pharmaceutically acceptable salt thereof with the effect of inhibiting T-type calcium channels and a medicament useful for the treatment of a disease associated with the activation of T-type calcium channels.
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
The present disclosure provides a method of detecting IgG4 and Smad1 in a biological sample from a subject with onset or a risk of onset of diabetic nephropathy.
The present invention provides: an assay method that uses a compound represented by formula (I) as a fluorescent probe molecule and that is for detecting the lipid peroxidation suppression activity of a test compound; an assay kit that uses the assay method; a screening method that uses the assay method; and a pharmaceutical composition that is for the treatment, etc. of diseases (such as age-related macular degeneration) that are induced by lipid peroxidation reactions.
The present invention provides: an assay method that uses a compound represented by formula (I) as a fluorescent probe molecule and that is for detecting the lipid peroxidation suppression activity of a test compound; an assay kit that uses the assay method; a screening method that uses the assay method; and a pharmaceutical composition that is for the treatment, etc. of diseases (such as age-related macular degeneration) that are induced by lipid peroxidation reactions.
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
The present invention provides: an assay method that uses a compound represented by formula (I) as a fluorescent probe molecule and that is for detecting the lipid peroxidation suppression activity of a test compound; an assay kit that uses the assay method; a screening method that uses the assay method; and a pharmaceutical composition that is for the treatment, etc. of diseases (such as age-related macular degeneration) that are induced by lipid peroxidation reactions.
C07C 57/00 - Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
C40B 20/08 - Direct analysis of the library members per se by physical methods, e.g. spectroscopy
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
FUSO PHARMACEUTICAL INDUSTRIES, LTD. (Japan)
Inventor
Kawabata, Atsufumi
Sekiguchi, Fumiko
Toyooka, Naoki
Okada, Takuya
Nishikawa, Hiroyuki
Abstract
The present invention provides a compound that has a T-type calcium channel blocking effect and that is represented by formula (I) [in the formula, R1, R2, R3, R4, k, l, m, and n are as defined in the description] or a pharmacologically acceptable salt thereof, and a drug that is useful in the treatment of diseases caused by activation of T-type calcium channels.
A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
7.
RESERVOIR ASSEMBLY FOR PROVIDING CARDIOPLEGIC SOLUTION CONTAINING BICARBONATE ION, AND METHOD FOR MANUFACTURING THE SAME
The object of the invention is to provide a novel reservoir assembly for providing a cardioplegic solution and a method for manufacturing the same. An aspect of the invention is to provide a reservoir assembly for providing a cardioplegic solution, comprising a multi-chamber reservoir; a gas-impermeable outer package packaging the multi-chamber reservoir; an oxygen detection agent and a deoxygenation agent in a space part between the multi-chamber reservoir and the outer package, wherein the deoxygenation agent neither generates nor absorbs carbon dioxide, wherein the multi-chamber reservoir comprises at least a first chamber, a second chamber, and a first separator wall that separates the two chambers, the first chamber holds a first medical liquid, the second chamber holds a second medical liquid containing bicarbonate ions, one or both of the first medical liquid and the second medical liquid contains potassium ions, the cardioplegic solution comprises the first medical liquid and the second medical liquid, and the cardioplegic solution contains bicarbonate ions of 5 to 20 mEq/L and potassium ions of 5 to 35 mEq/L. Another aspect of the invention is to provide a method for manufacturing the reservoir assembly for providing a cardioplegic solution.
B65D 81/32 - Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents for packaging two or more different materials which must be maintained separate prior to use in admixture
8.
Compound having PD-L1 expression-suppressing action
The present invention provides a compound of formula (I):
2, m and n are as defined in the specification, with an inhibitory effect of PD-L1 expression and an inhibitory effect of reduced production of IL-2 and a medicament useful for the treatment of a disease associated with the reduced immune function caused by the formation of PD-1/PD-L1 binding.
The present invention may provide a pharmaceutical composition for intraocular administration or oral administration, for preventing or treating a retinal disease (such as age-related macular degeneration), or suppressing a progression of the disease in a subject in need of treatment, the composition comprising an effective amount of one or more compounds selected from the following group, and a pharmaceutically acceptable carrier; and a method therefor, a group consisting of apomorphine, eseroline, ethoxyquin, methyldopa, olanzapine and indapamide.
Provided is a drug that suppresses the growth of tumor cells by specifically targeting mutant JAK2 and inhibiting hyperactivated JAK2. The following mutant (a) or (b) of erythropoietin. (a) A mutant erythropoietin obtained by introducing a mutation into human erythropoietin comprising the amino acid sequence of SEQ ID NO: 1, said mutant comprising an amino acid sequence derived from the amino acid sequence of SEQ ID NO: 1 by substitution of the 103rd arginine by another amino acid, wherein the amino acid substituting for the 103rd arginine decreases or reverses the positive charge of arginine. (b) A mutant erythropoietin which comprises an amino acid sequence derived from the amino acid sequence of mutant (a) by deletion, substitution or addition of one to several amino acids other than the 103rd amino acid and which inhibits erythropoietin signaling.
The disclosures as described herein a pharmaceutical composition for preventing or treating a cerebrovascular disorder or a vascular dementia, or suppressing a progression of the diseases in a subject in need of the treatment and so on, the composition comprising one or more compounds selected from the following group, and a pharmaceutically acceptable carrier; and a method using the same. A group consisting of apomorphine, eseroline, ethoxyquin, methyldopa, olanzapine, indapamide, and the others.
A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A23L 33/00 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof
A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives
The present application provides a method for an assisted reproductive technology comprising using a medium comprising a low caprylic acid-containing albumin; a medium for said method; and an agent for use in said medium.
NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (Japan)
FUSO PHARMACEUTICAL INDUSTRIES, LTD. (Japan)
Inventor
Suzuki, Yasuhiko
Nakagawa, Miki
Kameda, Yayoi
Konnai, Satoru
Okagawa, Tomohiro
Maekawa, Naoya
Goto, Shinya
Sajiki, Yamato
Ohashi, Kazuhiko
Murata, Shiro
Kitahara, Yuzuru
Yamamoto, Keiichi
Abstract
The present invention provides mammalian cell expression vectors that impart to mammalian host cells an ability to produce high levels of foreign gene-derived proteins. A ubiquitously acting chromatin opening element (UCOE) is introduced into an expression vector that has a plasmid DNA integrated into a transcriptional hot spot on the chromosome of a dihydrofolate reductase gene-deficient host cell so that it allows for selection of strains that grow in hypoxanthine-thymidine (hereinafter denoted as HT)-free medium, whereby transformants will produce a protein of interest in increased amounts.
C12N 15/67 - General methods for enhancing the expression
C12N 15/66 - General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligationUse of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
The present invention provides an anti-PD-L1 antibody capable of staining tumor cells such as melanoma cells.
An anti-PD-L1 antibody comprising (a) a light chain comprising CDR1 having the amino acid sequence of KSISKY (SEQ ID NO: 1), CDR2 having the amino acid sequence of SGS and CDR3 having the amino acid sequence of QQHNEYPLT (SEQ ID NO: 2) and (b) a heavy chain comprising CDR1 having the amino acid sequence of GYTFTDYI (SEQ ID NO: 3), CDR2 having the amino acid sequence of INPDSGGN (SEQ ID NO: 4) and CDR3 having the amino acid sequence of ARGITMMVVISHWKFDP (SEQ ID NO: 5). A composition for detecting PD-L1, comprising the above antibody as an active ingredient. A method for preparing the above antibody is also provided.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
15.
NOVEL COMPOUND HAVING PD-L1 EXPRESSION-SUPPRESSING ACTION
The present invention provides a compound having a PD-L1 expression-suppressing action and an IL-2 production reduction-suppressing action represented by formula (I): [in the formula: R1, R2, m, and n are as defined in the specification.] or a pharmaceutically acceptable salt thereof and a drug useful for treating diseases caused by compromised immune function due to PD-1/PD-L1 binding.
Provided are a novel reservoir for a cardioplegic solution and a method for manufacturing the same. A reservoir for a cardioplegic solution provided with a multi-chamber container, a gas-impermeable outside package body in which the multi-chamber container is packaged, and an oxygen sensing agent and an oxygen scavenger which neither generates nor absorbs carbon dioxide gas, said oxygen sensing agent and oxygen scavenger being disposed within a space between the multi-chamber container and the outside package body, wherein: the multi-chamber container comprises at least a first chamber, a second chamber and a first partition wall separating these two chambers; the first chamber holds a first pharmaceutical solution; the second chamber holds a second pharmaceutical solution containing bicarbonate ion; the first pharmaceutical solution and/or the second pharmaceutical solution contain potassium ion; and the cardioplegic solution comprises the first pharmaceutical solution and the second pharmaceutical solution and contains 5-20 mEq/L of bicarbonate ion and 5-35 mEq/L of potassium ion. A method for manufacturing the reservoir.
A61J 1/05 - Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids
B65D 81/32 - Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents for packaging two or more different materials which must be maintained separate prior to use in admixture
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
FUSO PHARMACEUTICAL INDUSTRIES, LTD. (Japan)
Inventor
Kawabata, Atsufumi
Sekiguchi, Fumiko
Tsubota, Maho
Toyooka, Naoki
Nishikawa, Hiroyuki
Abstract
A new analgesic has been developed for T-type calcium channels as therapeutic targets.
The present invention provides a T-type calcium channel inhibitor which is a compound represented by formula (1):
or a pharmaceutically acceptable salt or solvate thereof.
The present invention also provides this T-type calcium channel inhibitor, a medicament containing the T-type calcium channel inhibitor, and a therapeutic or prophylactic agent for a disease having an effective T-type calcium channel inhibitory action.
The present invention provides: a pharmaceutical composition that is to be intraocularly or orally administered for preventing or treating a retinal disease (e.g., age-related macular degeneration) of a patient who needs to be treated, or inhibiting the progression of the disease, and that contains a pharmaceutically-acceptable carrier and an effective amount of at least one compound selected from the group consisting of apomorphine, eseroline, ethoxyquin, methyldopa, olanzapine, indapamide, and the like; and a method.
A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
A61K 31/403 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
The present disclosure provides: a pharmaceutical composition that is for preventing or treating vascular dementia or a cerebrovascular disorder in a patient who needs to be treated, or inhibiting the progression of the disease, and that contains a pharmaceutically-acceptable carrier and at least one compound selected from the group consisting of apomorphine, eseroline, ethoxyquin, methyldopa, olanzapine, indapamide, and the like; and a method.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
20.
Therapeutic drug for lipid-peroxidation-induced diseases and screening method for therapeutic drugs for lipid-peroxidation-induced diseases
The present invention provides: an assay method that uses a compound represented by formula (I) as a fluorescent probe molecule and that is for detecting the lipid peroxidation suppression activity of a test compound; an assay kit that uses the assay method; a screening method that uses the assay method; and a pharmaceutical composition that is for the treatment, etc. of diseases (such as age-related macular degeneration) that are induced by lipid peroxidation reactions.
C07C 57/00 - Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
C40B 20/08 - Direct analysis of the library members per se by physical methods, e.g. spectroscopy
G01N 33/52 - Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper
21.
Detection reagents and kit for identifying oxidized state and glycated state of low-density lipoproteins
A detection reagent for comprehensively detecting an oxidized state and a glycated state of a low-density lipoprotein. While an oxidized low-density lipoprotein and a glycated low-density lipoprotein are detected with a fluolophore-labelled antibody, a lipid radical is detected with a fluorescent nitroxide 2,2,6-trimethyl-4-(4-nitrobenzo[1,2,5]oxadiazol-7-ylamino)-6-pentylpiperadine-1-oxyl (NBD-Pen).
G01N 21/78 - Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator producing a change of colour
G01N 33/533 - Production of labelled immunochemicals with fluorescent label
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
The present invention provides an anti-PD-L1 antibody capable of staining tumor cells such as melanoma cells.
An anti-PD-L1 antibody comprising (a) a light chain comprising CDR1 having the amino acid sequence of KSISKY (SEQ ID NO: 1), CDR2 having the amino acid sequence of SGS and CDR3 having the amino acid sequence of QQHNEYPLT (SEQ ID NO: 2) and (b) a heavy chain comprising CDR1 having the amino acid sequence of GYTFTDYI (SEQ ID NO: 3), CDR2 having the amino acid sequence of INPDSGGN (SEQ ID NO: 4) and CDR3 having the amino acid sequence of ARGITMMVVISHWKFDF (SEQ ID NO: 5). A composition for detecting PD-L1, comprising the above antibody as an active ingredient. A method for preparing the above antibody is also provided.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
23.
CULTURE MEDIUM FOR ASSISTED REPRODUCTION TECHNOLOGY
Provided are: an assisted reproductive technology method characterized by the use of a culture medium containing albumin having a low caprylic acid content; a culture medium for said method; and an agent for use in said culture medium.
Disulfide-type HMGB1-specific antibody, method for measuring disulfide-type HMGB1 and kit for said measurement, and measurement method capable of quantitating all of HMGB1 molecules including reduced HMGB1, disulfide-type HMGB1 and thrombin-cleavable HMGB1 and kit for said measurement
The present invention provides antibodies that show specific reactivity to disulfide-type HMGB1. Furthermore, the present invention provides methods for specifically measuring disulfide-type HMGB1 using the antibodies, and kits or reagents for the measurement. The present invention also provides methods for measuring total HMGB1 using such an antibody and an antibody that binds to both disulfide-type HMGB1 and reduced-type HMGB1 but does not bind to des-HMGB1, and kits or reagents for the measurement.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (Japan)
FUSO PHARMACEUTICAL INDUSTRIES,LTD. (Japan)
Inventor
Suzuki, Yasuhiko
Nakagawa, Miki
Kameda, Yayoi
Konnai, Satoru
Okagawa, Tomohiro
Maekawa, Naoya
Goto, Shinya
Sajiki, Yamato
Ohashi, Kazuhiko
Murata, Shiro
Kitahara, Yuzuru
Yamamoto, Keiichi
Abstract
Provided is an expression vector for mammalian cells, which imparts to mammalian host cells a high-level production capability for a protein derived from a foreign gene. The amount of a desired protein that is produced in a transformant is increased by a plasmid DNA being incorporated into a transfer hotspot on the chromosome of a dihydrofolate reducing enzyme gene-deficient host cell, the foregoing being achieved by introducing a ubiquitously-acting chromatin opening element (UCOE) to an expression vector configured for selection of a strain that grows in a culture that does not contain hypoxanthine thymidine (hereinafter referred to as "HT").
C12N 1/15 - Fungi Culture media therefor modified by introduction of foreign genetic material
C12N 1/19 - YeastsCulture media therefor modified by introduction of foreign genetic material
C12N 1/21 - BacteriaCulture media therefor modified by introduction of foreign genetic material
C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
C12P 21/02 - Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor
C12N 15/11 - DNA or RNA fragmentsModified forms thereof
Disclosed is a pain therapeutic drug that prevents or treats pain, and further, has a very low risk of hemorrhage. Provided is a pharmaceutical composition which is for preventing or treating pain and the anticoagulation action of which is suppressed, the composition containing, as an active ingredient, middle-molecular-weight heparin having an average molecular weight of 8500-9500, or amino acid derivatives of the middle-molecular-weight heparin.
The present invention provides a drug capable of preventing or treating diabetic nephropathy.
The present invention relates to a prophylactic and/or therapeutic drug for diabetic nephropathy, comprising a RARγ agonist as an active ingredient. The present invention also provides a prophylactic and/or therapeutic drug for renal anemia; a drug inhibiting the expression of type IV collagen in mesangial cells; a drug inhibiting the expression of BMP4 in mesangial cells; and a drug inhibiting fibrosis in the renal tubulointerstitium.
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A61K 9/00 - Medicinal preparations characterised by special physical form
The present invention provides an anti-PD-1 antibody capable of repeated administration even to animals other than rat. An anti-PD-1 antibody comprising (a) a light chain comprising a light chain variable region containing CDR1 having the amino acid sequence of QSLEYSDGYTY (SEQ ID NO: 16), CDR2 having the amino acid sequence of GVS and CDR3 having the amino acid sequence of FQATHDPDT (SEQ ID NO: 17) and the light chain constant region of an antibody of an animal other than rat; and (b) a heavy chain comprising a heavy chain variable region containing CDR1 having the amino acid sequence of GFSLTSYY (SEQ ID NO: 18), CDR2 having the amino acid sequence of IRSGGST (SEQ ID NO: 19) and CDR3 having the amino acid sequence of ARTSSGYEGGFDY (SEQ ID NO: 20) and the heavy chain constant region of an antibody of an animal other than rat. A pharmaceutical composition comprising the above-described anti-PD-1 antibody as an active ingredient. A method for preparing the anti-PD-1 antibody is also provided.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61P 35/02 - Antineoplastic agents specific for leukemia
The present invention provides an anti-LAG-3 antibody capable of repeated administration even to animals other than rat. An anti-LAG-3 antibody comprising (a) a light chain comprising a light chain variable region containing CDR1 having the amino acid sequence of QSLLDSDGNTY (SEQ ID NO: 16), CDR2 having the amino acid sequence of SVS and CDR3 having the amino acid sequence of MQATHVPFT (SEQ ID NO: 17) and the light chain constant region of an antibody of an animal other than rat; and (b) a heavy chain comprising a heavy chain variable region containing CDR1 having the amino acid sequence of GFDFDTYP (SEQ ID NO: 18), CDR2 having the amino acid sequence of ITIKTHNYAT (SEQ ID NO: 19) and CDR3 having the amino acid sequence of NREDFDY (SEQ ID NO: 20) and the heavy chain constant region of an antibody of an animal other than rat. A pharmaceutical composition comprising the above anti-LAG-3 antibody as an active ingredient. A method for preparing the above anti-LAG-3 antibody is also provided.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention has demonstrated that microorganisms present in a liver can be killed by washing the bile duct and the portal vein with hot water, and then disinfecting the liver using a chlorine-based disinfectant. It has also been demonstrated that sterilizing effects can be enhanced by freezing the liver after disinfection with a chlorine-based disinfectant.
A23L 13/20 - Meat productsMeat mealPreparation or treatment thereof from offal, e.g. rinds, skins, marrow, tripes, feet, ears or snouts
A23B 4/09 - FreezingSubsequent thawingCooling with addition of chemicals before or during cooling with direct contact between the food and the chemical, e.g. liquid N2, at cryogenic temperature
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
FUSO PHARMACEUTICAL INDUSTRIES, LTD. (Japan)
Inventor
Kawabata, Atsufumi
Sekiguchi, Fumiko
Tsubota, Maho
Toyooka, Naoki
Nishikawa, Hiroyuki
Abstract
Developed is a novel analgesic, the therapeutic targets of which are T-type calcium channels. The present invention provides a T-type calcium channel inhibitor which is a compound represented by formula (1), a pharmaceutically acceptable salt of this compound, or a solvate of this compound. The present invention also provides: this T-type calcium channel inhibitor; a pharmaceutical product which contains this T-type calcium channel inhibitor; and a therapeutic agent or prophylactic agent for diseases, the effective action of which is T-type calcium channel inhibitory activity. (In the formula, each of R1and R2independently represents H or -OH; R3represents -OH; R4represents -OH or -H; and R5 represents a linear or branched alkyl or cycloalkyl alkyl group having 1-10 carbon atoms, or a linear or branched alkenyl or cycloalkyl alkenyl group having 2-10 carbon atoms.)
The present invention provides a medicament useful for treatment and/or prevention of cancer, a vaccine adjuvant, and an inhibitor of immune checkpoint comprising a compound of formula (I):
8, and n are as defined in the present specification.
C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 491/052 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
A61K 39/00 - Medicinal preparations containing antigens or antibodies
33.
COMBINATION USE OF INHIBITOR TARGETING PD-1/PD-L1 AND COX-2 INHIBITOR
NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (Japan)
FUSO PHARMACEUTICAL INDUSTRIES,LTD. (Japan)
Inventor
Konnai, Satoru
Ohashi, Kazuhiko
Murata, Shiro
Okagawa, Tomohiro
Maekawa, Naoya
Nishimori, Asami
Goto, Shinya
Suzuki, Yasuhiko
Nakajima, Chie
Sajiki, Yamato
Abstract
Provided are: a new therapeutic strategy by using an inhibitor that targets PD-1/PD-L1; a pharmaceutical composition which contains a COX-2 inhibitor and is administered at any period of time prior to, subsequent to, or at the same time of the administering of the inhibitor targeting PD-1/PD-L1; and an immunostimulating effect enhancer which is for the inhibitor targeting PD-1/PD-L1 and contains a COX-2 inhibitor.
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 31/196 - Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
A61K 31/341 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
A61K 31/403 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
A61K 31/5415 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
A61K 31/63 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
34.
THERAPEUTIC DRUG FOR LIPID-PEROXIDATION-INDUCED DISEASES AND SCREENING METHOD FOR THERAPEUTIC DRUGS FOR LIPID-PEROXIDATION-INDUCED DISEASES
The present invention provides: an assay method that uses a compound represented by formula (I) as a fluorescent probe molecule and that is for detecting the lipid peroxidation suppression activity of a test compound; an assay kit that uses the assay method; a screening method that uses the assay method; and a pharmaceutical composition that is for the treatment, etc. of diseases (such as age-related macular degeneration) that are induced by lipid peroxidation reactions.
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
A61K 31/198 - Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
A61K 31/245 - Amino benzoic acid types, e.g. procaine, novocaine
A61K 31/4045 - Indole-alkylaminesAmides thereof, e.g. serotonin, melatonin
A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A novel highly stable sodium diacetate crystal, in which the volatilization of acetic acid can be suppressed for a long period. More specifically, a sodium diacetate crystal having a median diameter in the range of 300 to 3000 μm.
[Problem] To provide a method of scavenging an unstable radical derived from a lipid and analyzing structures of those radicals.
[Means for solution] A fluorescent nitroxide (NBD-Pen) is made to act to scavenge a lipid radical or a fragment radical thereof, and fluorescent detection liquid chromatography (LC/FL) and mass spectrometry (MS) are combined to identify lipid-derived radicals contained in a lipid extract.
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
G01N 33/92 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving lipids, e.g. cholesterol
C11C 1/00 - Preparation of fatty acids from fats, fatty oils, or waxesRefining the fatty acids
G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances
C11B 1/10 - Production of fats or fatty oils from raw materials by extracting
C07D 271/12 - Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
37.
DETECTION REAGENT AND KIT FOR IDENTIFYING ACIDIC STATE AND GLYCATION STATE OF LOW DENSITY LIPOPROTEIN
The present invention provides a detection reagent for comprehensively detecting the oxidation state and glycation state of a low density lipoprotein. More particularly, according to the present invention, an oxidized low density lipoprotein and a glycated lipoprotein are detected by using a chromophore-labeled antibody, and a lipid radical is detected by using fluorescent nitroxide, 2,2,6-trimethyl-4-(4-nitrobenzo[1,2,5]oxadiazol-7-ylamino)-6-pentylpiperadine-1-oxyl (NBD-Pen).
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
G01N 21/78 - Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated by observing the effect on a chemical indicator producing a change of colour
NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (Japan)
FUSO PHARMACEUTICAL INDUSTRIES,LTD. (Japan)
Inventor
Konnai, Satoru
Ohashi, Kazuhiko
Murata, Shiro
Okagawa, Tomohiro
Nishimori, Asami
Maekawa, Naoya
Takagi, Satoshi
Kagawa, Yumiko
Suzuki, Yasuhiko
Nakajima, Chie
Abstract
Provided is an anti-PD-L1 antibody capable of staining tumor cells such as melanoma. The anti-PD-L1 antibody comprises: (a) an L-chain which includes CDR1 having the amino acid sequence KSISKY (SEQ ID NO: 1), CDR2 having the amino acid sequence SGS and CDR3 having the amino acid sequence QQHNEYPLT (SEQ ID NO: 2); and (b) an H-chain which includes CDR1 having the amino acid sequence GYTFTDYI (SEQ ID NO: 3), CDR2 having the amino acid sequence INPDSGGN (SEQ ID NO: 4) and CDR3 having the amino acid sequence ARGITMMVVISHWKFDF (SEQ ID NO: 5). A composition for detecting PD-L1, said composition comprising the anti-PD-L1 antibody as an active ingredient. Also provided is a method for producing the anti-PD-L1 antibody.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor
DISULFIDE-TYPE HMGB1-SPECIFIC ANTIBODY, METHOD FOR MEASURING DISULFIDE-TYPE HMGB1 AND KIT FOR SAID MEASUREMENT, AND MEASUREMENT METHOD CAPABLE OF QUANTITATING ALL OF HMGB1 MOLECULES INCLUDING REDUCED HMGB1, DISULFIDE-TYPE HMGB1 AND THROMBIN-CLEAVABLE HMGB1 AND KIT FOR SAID MEASUREMENT
Provided is an antibody capable of exhibiting a reaction specific to disulfide-type HMGB1. Also provided are: a method for specifically measuring disulfide-type HMGB1 with the antibody; and a kit or a reagent for the measurement. Also provided are: a method for measuring all of HMGB1 molecules with the antibody and an antibody capable of binding to both of disulfide-type HMGB1 and reduced HMGB1 and incapable of binding to des-HMGB1; and a kit or a reagent for the measurement.
Provided is an inspection method which enables specific diagnosis of the pathological state of diabetic nephropathy at an early stage. The method, which aims at the detection of the onset or onset risk of diabetic nephropathy, comprises measuring IgG4 in a biological sample derived from a subject. The inspection method may further comprise measuring Smad1 in the biological sample derived from the subject, said method preferably comprising measuring both.
C07D 311/32 - 2, 3-Dihydro derivatives, e.g. flavanones
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (Japan)
FUSO PHARMACEUTICAL INDUSTRIES, LTD. (Japan)
Inventor
Konnai, Satoru
Ohashi, Kazuhiko
Murata, Shiro
Okagawa, Tomohiro
Nishimori, Asami
Maekawa, Naoya
Suzuki, Yasuhiko
Nakajima, Chie
Abstract
Provided is an anti-PD-L1 antibody that can be frequently administered to animals other than rats. The anti-PD-L1 antibody contains (a) an L-chain and (b) an H-chain. Said L-chain has: an L-chain-variable region including CDR1 that has the amino acid sequence QSLLYSENQKDY (SEQ ID NO: 37), CDR2 that has the amino acid sequence WAT, and CDR3 that has the amino acid sequence GQYLVYPFT (SEQ ID NO: 38); and an L-chain-constant region of an antibody of an animal other than a rat. Said H-chain has: an H-chain-variable region including CDR1 that has the amino acid sequence GYTFTSNF (SEQ ID NO: 39), CDR2 that has the amino acid sequence IYPEYGNT (SEQ ID NO: 40), and CDR3 that has the amino acid sequence ASEEAVISLVY (SEQ ID NO: 41); and an H-chain-constant region of an antibody of an animal other than a rat. A pharmaceutical composition comprising the anti-PD-L1 antibody as an active ingredient. A method of producing the anti-PD-L1 antibody is also provided.
NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (Japan)
FUSO PHARMACEUTICAL INDUSTRIES, LTD. (Japan)
Inventor
Konnai, Satoru
Ohashi, Kazuhiko
Murata, Shiro
Okagawa, Tomohiro
Nishimori, Asami
Maekawa, Naoya
Suzuki, Yasuhiko
Nakajima, Chie
Abstract
Provided is an anti-PD-1 antibody that can be administered frequently even to animals other than rats. An anti-PD-1 antibody including: (a) an L chain that has an L chain variable region including CDR1 having the amino acid sequence of QSLEYSDGYTY (SEQ ID NO: 16), CDR2 having the amino acid sequence of GVS, and CDR3 having the amino acid sequence of FQATHDPDT (SEQ ID NO: 17), and also has an L chain constant region of an animal antibody other than rat; and (b) an H chain that has an H chain variable region including CDR1 having the amino acid sequence of GFSLTSYY (SEQ ID NO: 18), CDR2 having the amino acid sequence of IRSGGST (SEQ ID NO: 19), and CDR3 having the amino acid sequence of ARTSSGYEGGFDY (SEQ ID NO: 20), and also has an H chain constant region of an animal antibody other than rat. A pharmaceutical composition containing the anti-PD-1 antibody as an active ingredient. Also provided is a method for producing the anti-PD-1 antibody.
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (Japan)
FUSO PHARMACEUTICAL INDUSTRIES, LTD. (Japan)
Inventor
Konnai, Satoru
Ohashi, Kazuhiko
Murata, Shiro
Okagawa, Tomohiro
Nishimori, Asami
Maekawa, Naoya
Suzuki, Yasuhiko
Nakajima, Chie
Abstract
Provided is an anti-LAG-3 antibody that can be frequently administered to a non-rat animal. The anti-LAG-3 antibody comprises: (a) an L chain comprising an L-chain variable region that includes CDR1 having a QSLLDSDGNTY (SEQ ID NO. 16) amino acid sequence, CDR2 having an SVS amino acid sequence, and CDR3 having an MQATHVPFT (SEQ ID NO. 17) amino acid sequence, and an L-chain constant region of a non-rat mammalian antibody; and (b) an H chain comprising an H-chain variable region that includes CDR1 having a GFDFDTYP (SEQ ID NO. 18) amino acid sequence, CDR2 having an ITIKTHNYAT (SEQ ID NO. 19) amino acid sequence, and CDR3 having an NREDFDY (SEQ ID NO. 20) amino acid sequence, and an H-chain constant region of a non-rat mammalian antibody. Also provided is a pharmaceutical composition containing the anti-LAG-3 antibody as an active ingredient. Also provided is a method of producing the anti-LAG-3 antibody.
A61P 35/02 - Antineoplastic agents specific for leukemia
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention provides a therapeutic agent useful for the treatment and/or prophylaxis of cancer, a vaccine adjuvant, and an immune checkpoint inhibitor, comprising a compound represented by formula (I) or a pharmaceutically acceptable salt thereof. (I) [In the formula, a to d, ring A, R1, R1', R2, R2', R3 to R8, and n are defined in the Description.]
C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
A61K 31/435 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
C07D 491/052 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
46.
IMMUNOLOGICAL TEST METHOD AND IMMUNOLOGICAL TEST KIT
In the present invention, it was found that, when measuring HMGB1 in a sample, using an antibody that binds to both HMGB2 and HMGB1, the reaction between HMGB2 and the HMGB1 antibody can be suppressed by also including an HMGB2 absorber (an HMGB2 antibody and/or an HMGB2 derived peptide that inhibits the binding of HMGB2 and the HMGB1 antibody). In other words, it was revealed that the HMGB1 in the sample alone can be measured or detected by contacting the HMGB1 antibody and the sample in the presence of the HMGB2 absorber.
G01N 33/531 - Production of immunochemical test materials
C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
47.
Nucleic acid detection or quantification method using mask oligonucleotide, and device for same
Very simple, highly sensitive detection or quantification of target nucleic acids of interest has been achieved by: hybridizing mask oligonucleotides to regions in a single-stranded region of a nucleic acid to be assayed between which a region to be hybridized by an oligonucleotide probe is positioned, thereby opening the probe-hybridizing region and keeping the single-stranded region of the target nucleic acid stable, and then subjecting this nucleic acid having the single-stranded region to nucleic acid chromatography.
NATIONAL UNIVERSITY CORPORATION GUNMA UNIVERSITY (Japan)
FUSO PHARMACEUTICAL INDUSTRIES, LTD. (Japan)
Inventor
Kikuchi, Haruhisa
Oshima, Yoshiteru
Hattori, Toshio
Kubohara, Yuzuru
Yamada, Osamu
Zhang, Jing
Matsushita, Yoshihisa
Kida, Shinya
Abstract
The present invention provides a useful medicament for the treatment and/or prophylaxis of a disease associated with the enhancement of OPN production including cancer, which comprises a compound of formula:
7, m, n, p, X, and Y are as defined in the specification, a pharmaceutically acceptable salt thereof.
C07C 235/50 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms not being part of nitro or nitroso groups
C07C 235/48 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
C07C 233/36 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
C07C 233/78 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
C07C 233/62 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
C07D 309/08 - Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
C07C 235/60 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho- position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
C07C 237/22 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
C07C 237/42 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
C07D 209/14 - Radicals substituted by nitrogen atoms, not forming part of a nitro radical
C07C 237/34 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms not being part of nitro or nitroso groups
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/4045 - Indole-alkylaminesAmides thereof, e.g. serotonin, melatonin
A61K 31/4409 - Non-condensed pyridinesHydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
A61K 31/351 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
A61K 31/397 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
A61K 31/166 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
C07D 205/04 - Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
C07D 207/16 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D 211/60 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D 333/38 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
49.
Sodium diacetate crystal and solid dialysis preparation comprising said crystal
A novel highly stable sodium diacetate crystal, in which the volatilization of acetic acid can be suppressed for a long period. More specifically, a sodium diacetate crystal having a median diameter in the range of 300 to 3000 μm.
A syringe and a syringe set are provided. The syringe can be readily distinguished from other syringes only by viewing a tip of the syringe. The syringe includes a tip provided at an end of a barrel body to be filled with a medicine and having an outer diameter of 4.315 mm to 6 mm, a peripheral wall provided around the tip concentrically with the tip, and a helical rib formed on an inner the of the peripheral wall or an outer face of the tip.
Disclosed is a hemostatic agent applicator capable of effectively placing a fluid hemostatic agent on an incision surface. The present invention is a hemostatic agent applicator for use in disposing a fluid hemostatic agent, including a tool body in which a hollow part surrounded by a wall part is formed and which includes an open end part on a downstream side of the wall part, and an inlet provided to a portion of the wall part of the tool body to communicate with the hollow part. This hemostatic agent applicator is useful in medical settings relating to surgical procedures, particularly for surface bleeding of a liver and internal organ surgery such as a spleen and fibroid enucleation. An applicator further reduced in size can be applied not only in abdominal surgery, but in endoscopic surgery as well.
A61B 17/12 - Surgical instruments, devices or methods for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord
53.
Osteopontin production inhibitor containing dictyopyrone derivative or dihydrodictyopyrone derivative as active ingredient
NATIONAL UNIVERSITY CORPORATION GUNMA UNIVERSITY (Japan)
FUSO PHARMACEUTICAL INDUSTRIES, LTD. (Japan)
Inventor
Kikuchi, Haruhisa
Oshima, Yoshiteru
Hattori, Toshio
Kubohara, Yuzuru
Yamada, Osamu
Zhang, Jing
Matsushita, Yoshihisa
Kida, Shinya
Abstract
Disclosed herein is an osteopontin production inhibitor capable of preventing a disease resulting from increased production of osteopontin. The osteopontin production inhibitor contains a dictyopyrone derivative or a dihydrodictyopyrone derivative as an active ingredient. The dictyopyrone derivative is preferably a compound represented by Chemical Formula 1 or 2, and the dihydrodictyopyrone derivative is preferably a compound represented by Chemical Formula 3 or 4.
C07D 213/02 - Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
A61K 31/45 - Non-condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
A61K 31/366 - Lactones having six-membered rings, e.g. delta-lactones
A61K 31/4412 - Non-condensed pyridinesHydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
54.
Model animal for pregnancy-induced hypertension syndrome, and treatment method therefor
A lentiviral vector was used to produce non-human animals that express human sFLT1 specifically in the murine placenta, to provide model animals of diseases such as pregnancy-induced hypertension syndrome that are close to the clinical conditions, methods for producing the model animals, methods of screening for candidate compounds as therapeutic agents for diseases such as pregnancy-induced hypertension syndrome by using the model animals, and therapeutic agents for diseases such as pregnancy-induced hypertension syndrome. As a result, the model animals were found to exhibit symptoms that are very close to the clinical conditions in human, which are presentation of hypertension as well as placental insufficiency, intrauterine growth retardation, glomerulosclerosis, and proteinuria during pregnancy, and improvement of those symptoms postpartum. Furthermore, when pravastatin was administered to this model animal, it was found that diseases such as pregnancy-induced hypertension syndrome were improved by the activation of placenta-derived growth factor (PIGF) which antagonizes sFLT1.
NATIONAL UNIVERSITY CORPORATION GUNMA UNIVERSITY (Japan)
FUSO PHARMACEUTICAL INDUSTRIES, LTD. (Japan)
Inventor
Kikuchi, Haruhisa
Oshima, Yoshiteru
Hattori, Toshio
Kubohara, Yuzuru
Yamada, Osamu
Zhang, Jing
Matsushita, Yoshihisa
Kida, Shinya
Abstract
The present invention provides a therapeutic agent useful in the treatment and/or prevention of conditions, including cancer, caused by enhanced OPN production, the therapeutic agent containing a compound represented by the formula (in the formula, R1, R2, R3, R4, R5, R6, R7, m, n, p, X, and Y are as defined in the specification) or a pharmaceutically acceptable salt thereof.
C07C 235/50 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms not being part of nitro or nitroso groups
A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
A61K 31/166 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
A61K 31/351 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
A61K 31/4045 - Indole-alkylaminesAmides thereof, e.g. serotonin, melatonin
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 11/00 - Drugs for disorders of the respiratory system
A61P 13/04 - Drugs for disorders of the urinary system for urolithiasis
A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
A61P 19/10 - Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
A61P 25/00 - Drugs for disorders of the nervous system
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C07C 233/36 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
C07C 233/62 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
C07C 233/78 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
C07C 235/48 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
C07C 235/60 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho- position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
C07C 237/22 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
C07C 237/42 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
C07D 209/14 - Radicals substituted by nitrogen atoms, not forming part of a nitro radical
C07D 309/08 - Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
56.
NUCLEIC ACID DETECTION AND ASSAY METHOD USING MASK OLIGONUCLEOTIDE, AND DEVICE FOR SAME
Through the present invention, a mask oligonucleotide is hybridized in regions on either side of a region in which an oligonucleotide probe is hybridized in a single-stranded region of a nucleic acid to be assayed, the region in which the probe is hybridized is thereby opened and the single-stranded region of the target nucleic acid is maintained in a stable state. By then subjecting the nucleic acid having such a single-stranded region to nucleic acid chromatography, the desired target nucleic acid is detected and quantified with high sensitivity by an extremely simple process.
Osaka Prefecture University Public Corporation (Japan)
Fuso Pharmaceutical Industries, Ltd. (Japan)
Inventor
Yamasaki, Shinji
Samosorunsuk, Worada
Asakura, Masahiro
Abstract
C. hyointestinalis by 16S rRNA gene analysis. Furthermore, the entire nucleotide sequence of the cdt genes was determined by genome walking upstream and downstream of the cdtB gene.
A novel highly stable sodium diacetate crystal capable of limiting volatilization of acetic acid for long periods. More specifically, a sodium diacetate crystal having a median diameter in the range of 300-3000 µm.
The present invention provides a high purity heparin useful to be a pharmaceutical product, cosmetics, research reagent, or the like, and a method for producing the same, more specifically, a heparin which does not substantially contain a nitrous acid degradation-resistant impurity and a method for producing a heparin, comprising mixing an aqueous solution of 5 to 30% by weight of the heparin with ethanol having an amount (volume) 0.2 to 1 times the amount (volume) of the aqueous heparin solution to obtain a colloidal precipitate of heparin.
Provided are a syringe and a syringe set. The syringe can be readily distinguished from other syringes simply by looking at a tip section thereof. The syringe comprises: the tip section (15) having an external diameter of 4.315-6 mm and provided at an end of a barrel main body (11) having a drug filled therein; a peripheral wall section (18) provided on the outer circumference of the tip section (15) and concentrically with the tip section (15); and a helical rib (19) provided on an inner surface of the peripheral wall section (18) or the outer surface of the tip section (15).
The present invention secures the airway, even when the root of the tongue falls back into the airway, without disturbing sleep. An airway expansion device (1) has a configuration characterized by being provided with the following: a pillow section (2) for supporting a cranial section; a left-right pair of lower jaw retention sections (3) for retaining the lower jaw which is coupled to the cranial section at the temporomandibular joint; a first actuating mechanism (4) for causing the lower jaw retention sections to abut the lower jaw; and a second actuating mechanism (5) for lifting the lower jaw retention sections with respect to the pillow section in the state where the lower jaw retention sections abut the lower jaw. The configuration is also characterized in that the lower jaw is maintained in the lifted state.
The present invention provides a T-type calcium channel inhibitor which is a compound represented by formula (1), a pharmaceutically acceptable salt of this compound or a solvate of this compound. The present invention also provides: this T-type calcium channel inhibitor; a pharmaceutical product containing this T-type calcium channel inhibitor; and a therapeutic agent or prophylactic agent for diseases, the effective action of which is a T-type calcium channel inhibitory action. (In formula (1), each of R1 and R2 independently represents H, -OH or -OR11, wherein R11 represents a C1-3 alkyl group; each of R3 and R4 independently represents H, -OH or -OR12, wherein R12 represents a C1-3 alkyl group; and each of R5 and R6 independently represents H, a halogen atom, a C1-10 alkyl group, a C2-6 alkenyl group, a C2-6 alkynyl group, a phenyl group (which may be substituted by a C1-6 alkoxy group or a halogen atom), a -C1-3 alkyl-phenyl group (which may be substituted by a C1-6 alkyloxy group or a halogen atom) or a C10-50 prenyl group.)
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61P 3/14 - Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
A61P 25/04 - Centrally acting analgesics, e.g. opioids
NATIONAL UNIVERSITY CORPORATION CHIBA UNIVERSITY (Japan)
FUSO PHARMACEUTICAL INDUSTRIES, LTD. (Japan)
Inventor
Oda, Shigeto
Sadahiro, Tomohito
Nakamura, Masataka
Tanaka, Syuichi
Tokuoka, Shogo
Otani, Hiroya
Abstract
The invention relates to a stable bicarbonate ion-containing drug solution, particularly a bicarbonate-containing drug solution for dialysis in which the stability has been improved by the presence of a phosphate ion. Further, the invention relates to a drug solution for acute blood purification, particularly a dialysate and a substitution liquid for acute blood purification to be mixed before use containing the drug solution. Still further, the invention relates to a dialysate and a substitution liquid for acute blood purification to be mixed before use in which the formation of insoluble fine particles or precipitates is prevented for a long time after mixing and with which hypokalemeia and hypophosphatemia are not caused.
A61M 1/16 - Dialysis systemsArtificial kidneysBlood oxygenators with membranes
B65D 81/32 - Containers, packaging elements, or packages, for contents presenting particular transport or storage problems, or adapted to be used for non-packaging purposes after removal of contents for packaging two or more different materials which must be maintained separate prior to use in admixture
NATIONAL UNIVERSITY CORPORATION GUNMA UNIVERSITY (Japan)
FUSO PHARMACEUTICAL INDUSTRIES, LTD. (Japan)
Inventor
Kikuchi, Haruhisa
Oshima, Yoshiteru
Hattori, Toshio
Kubohara, Yuzuru
Yamada, Osamu
Zhang, Jing
Matsushita, Yoshihisa
Kida, Shinya
Abstract
The purpose of the present invention is to provide an osteopontin production inhibitor which is capable of preventing a disease caused by enhanced osteopontin production. The osteopontin production inhibitor comprises a dictyopyrone derivative or a dihydrodictyopyrone derivative as an active ingredient. The dictyopyrone derivative is preferably a compound represented by chemical formula (1) or chemical formula (2). The dihydrodictyopyrone derivative is preferably a compound represented by chemical formula (3) or chemical formula (4).
Provided is a composition for embryo culture, which contains a constitution suitable for embryo culture. Provided is a composition for embryo culture, which contains (a) a constitution shown in Table A below.
C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
C12N 1/00 - Microorganisms, e.g. protozoaCompositions thereofProcesses of propagating, maintaining or preserving microorganisms or compositions thereofProcesses of preparing or isolating a composition containing a microorganismCulture media therefor
C12N 5/073 - Embryonic cells or tissuesFoetal cells or tissues
Disclosed is a hemostatic agent applicator capable of effectively placing a fluid hemostatic agent on an incision surface. The present invention is a hemostatic agent applicator for use in placing a fluid hemostatic agent, the applicator having: a tool main body which is surrounded by a wall part, forms a hollow part, and has an open end part on a downstream side of the wall part; and an inlet provided to a portion of the wall part of the tool main body and communicated with the hollow part. This hemostatic agent applicator is useful in medical settings relating to surgical procedures, particularly for liver surface bleeding and internal organ surgery such as spleen and fibroid enucleation. An applicator further reduced in size can be applied not only in abdominal surgery, but in endoscopic surgery as well.
In the present invention, it was found to be possible to sterilize a liver with respect to microorganisms existing therein by boiling water lavage of bile ducts and the pylorum and then disinfection of the liver using a chlorine-based disinfectant. Further, after disinfection using a chlorine-based disinfectant, it was found to be possible to further enhance the sterilizing effect by freezing the liver.
A lentiviral vector was used to produce non-human animals that express human sFLT1 specifically in the murine placenta, to provide model animals of diseases such as pregnancy-induced hypertension syndrome that are close to the clinical conditions, methods for producing the model animals, methods of screening for candidate compounds as therapeutic agents for diseases such as pregnancy-induced hypertension syndrome by using the model animals, and therapeutic agents for diseases such as pregnancy-induced hypertension syndrome. As a result, the model animals were found to exhibit symptoms that are very close to the clinical conditions in human, which are presentation of hypertension as well as placental insufficiency, intrauterine growth retardation, glomerulosclerosis, and proteinuria during pregnancy, and improvement of those symptoms postpartum. Furthermore, when pravastatin was administered to this model animal, it was found that diseases such as pregnancy-induced hypertension syndrome were improved by the activation of placenta-derived growth factor (PIGF) which antagonizes sFLT1.
The present invention provides a high purity heparin useful to be a pharmaceutical product, cosmetics, research reagent, or the like, and a method for producing the same, more specifically, a heparin which does not substantially contain a nitrous acid degradation-resistant impurity and a method for producing a heparin, comprising mixing an aqueous solution of 5 to 30% by weight of the heparin with ethanol having an amount (volume) 0.2 to 1 times the amount (volume) of the aqueous heparin solution to obtain a colloidal precipitate of heparin.
The present invention relates to providing a simple and highly reproducible method for measuring acetic acid concentration in blood plasma using gas chromatography/mass spectrometry (GC/MS), and more specifically relates to a method for measuring acetic acid concentration in blood plasma using gas chromatography/mass spectrometry (GC/MS), comprising a step for extracting acetic acid in blood plasma using methyl-tert-butyl ether (MTBE).
G01N 1/10 - Devices for withdrawing samples in the liquid or fluent state
G01N 27/62 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating the ionisation of gases, e.g. aerosolsInvestigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electric discharges, e.g. emission of cathode
G01N 30/04 - Preparation or injection of sample to be analysed
The purpose of the present invention is to provide a novel drug or method that uses buprenorphine or a pharmaceutically acceptable salt thereof. A drug for alleviating pain associated with disc herniation, pain associated with osteoarthritis of the spine, or pain associated with spinal canal stenosis, the drug attaching to the oral mucosa and containing buprenorphine or a pharmaceutically acceptable salt thereof.
Provided is a novel compound having an effective anti-cancer activity.
The novel compound according to the present invention includes a compound represented by formula (I):
or a pharmaceutically acceptable salt thereof.
A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
C07D 417/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
Provided is a composition for embryo culture, which comprises a constitutional composition suitable for embryo culture. Provided is a composition for embryo culture, which comprises (a) a constitutional composition shown in table (A).
National University Corporation Hokkaido University (Japan)
Fuso Pharmaceutical Industries, Ltd. (Japan)
Inventor
Tahara, Hiroshi
Suzuki, Yusuke
Yamamoto, Keiichi
Kitahara, Yuzuru
Suzuki, Yasuhiko
Abstract
The present inventors conducted dedicated studies and successfully constructed expression vectors that enable high-level production of foreign gene-derived proteins in mammalian host cells, which comprise a translation-impaired dihydrofolate reductase gene cistron whose expression has been attenuated by altering the codons to the least frequently used codons in mammals; and a gene cassette which has a cloning site for incorporation of a foreign gene between a highly transcriptionally active promoter and a highly stable polyadenylation signal.
OSAKA PREFECTURE UNIVERSITY PUBLIC CORPORATION (Japan)
Inventor
Yamasaki, Shinji
Asakura, Masahiro
Abstract
The present invention provides an improved filter method capable of more increasing the isolation rate of spirillum than the existing filter method and a device to be used for the same, and more specifically, a device for isolating spirillum, the device including a filter composed of polycarbonate, and an isolation method for spirillum using the device.
C12M 1/34 - Measuring or testing with condition measuring or sensing means, e.g. colony counters
C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor
C12Q 1/24 - Methods of sampling, or inoculating or spreading a sampleMethods of physically isolating an intact microorganism
The present invention provides a high purity heparin useful as a medicine, a cosmetic, a research reagent and the like, and a production method therefor, in more detail, a method for producing heparin, the method comprising mixing a heparin without substantially containing nitrous acid degradation-resistant impurities with 0.2 to 1 time (volume) the amount of ethanol to 5 to 30 wt% of heparin solution, and obtaining a colloidal precipitate of heparin.
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
National University Corporation Hokkaido University (Japan)
Fuso Pharmaceutical Industries, Ltd. (Japan)
Inventor
Suzuki, Yusuke
Tahara, Hiroshi
Yamamoto, Keiichi
Kitahara, Yuzuru
Suzuki, Yasuhiko
Abstract
As a result of dedicated research, the present inventors have successfully invented a collagen gene construct which can be easily purified and maintains a triple helix structure equivalent to that of naturally-occurring collagen while having a low molecular weight. Specifically, one-step purification by affinity purification is enabled because CR-D (a signal peptide) has a carbohydrate recognition domain. By substituting a portion of a human collagen structural gene of the present invention with the collagen-like structural gene portion of MBL, a low-molecular-weight collagen which maintains a triple helix structure and is thermally stable can be obtained with high purity and in large quantities.
C12P 21/06 - Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
82.
BENZOFURANONE COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING SAME
Provided is a novel compound having effective anticancer activity. This novel compound contains a compound represented by formula (I) [In the formula, R1 is C2-6 alkoxyalkyl group] or a pharmaceutically acceptable salt thereof.
C07D 417/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
A composition for promoting lacrimal secretion which can be used safely and effectively in the lacrimal secretion promoting therapy, not in the conventional supplemental therapy of lacrimal fluid components is provided. The composition for promoting lacrimal secretion comprising a peptide derivative represented by the formula (I):
and a contact lens which retains and/or contains the composition are provided.
Disclosed is a polypeptide of use in the development of reagents or medicines favourable to application for prevention or treatment of ischemic disorders such as conditions caused by ateriosclerosis. The polypeptide has at least one part containing an amino acid of sequence ID 1, and also enhances expression levels of the amino acid in mammalian blood vessels removed from ischemic conditions by means of blood reperfusion.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
85.
MODEL ANIMAL FOR PREGNANCY-INDUCED HYPERTENSION SYNDROME, AND TREATMENT METHOD THEREFOR
Provided are: a model animal which closely models actual clinical cases of disorders such as pregnancy-induced hypertension syndrome; a method for producing said model animal; a screening method using said model animal to screen candidate therapeutic compounds for disorders such as pregnancy-induced hypertension syndrome; and a therapeutic agent for disorders such as pregnancy-induced hypertension syndrome. In order to provide the above, a lentiviral vector was used on a mouse placenta to create a non-human animal that specifically expresses human sFLT1. The resulting model animal exhibited symptoms extremely close to actual human clinical cases; namely: hypertension, placental dysfunction, intrauterine fetal growth retardation, glomerulosclerosis, and proteinuria during pregnancy, with said symptoms exhibiting improvement following delivery. Furthermore, administering pravastatin to the model animal caused amelioration of disorders such as pregnancy-induced hypertension syndrome due to activation of placenta growth factor (PlGF), which is antagonistic towards sFLT1.
Provided are an airway widening tool and an airway widening unit having same, with which it is possible to open the airway reliably when the user is lying in the supine position and which also allow the user to change positions freely. The disclosed airway widening tool (1) is used by being attached to the outer periphery of the human neck, and includes: a main body (2) which comes into contact with the posterior side of the neck when the tool is worn and which receives an upward external force when the user is lying in the supine position; and a pair of jaw retainers (3a, 3b) which extend frontward from the main body (2) while being spaced apart from one another by a distance equivalent to the diameter of the neck, the jaw retainers coming into contact with the opposite sides of the lower jaw when the tool is worn. The main body (2) and the jaw retainers (3a, 3b) are formed of a restorable component. When the user changes his/her position from the supine position, the main body (2) and the jaw retainers (3a, 3b) deform in conformity with the user's position. When the user returns to the supine position, the external force received by the main body (2) acts on the jaw retainers (3a, 3b) which thereby retain the lower jaw at a height at which the airway can be opened.
A47C 21/00 - Attachments for beds, e.g. sheet holders or bed-cover holders Ventilating, cooling or heating means in connection with bedsteads or mattresses
C. hyointestinalis by 16S rRNA gene analysis. Furthermore, the entire nucleotide sequence of the cdt genes was determined by genome walking upstream and downstream of the cdtB gene.
C12P 21/06 - Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
88.
Campylobacter by targeting cytolethal distending toxin
C. hyointestinalis by 16S rRNA gene analysis. Furthermore, the entire nucleotide sequence of the cdt genes was determined by genome walking upstream and downstream of the cdtB gene.
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
89.
EXPRESSION VECTOR FOR PRODUCING PROTEIN DERIVED FROM FOREIGN GENE IN LARGE QUANTITY USING ANIMAL CELLS, AND USE THEREOF
NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (Japan)
FUSO PHARMACEUTICAL INDUSTRIES, LTD. (Japan)
Inventor
Tahara, Hiroshi
Suzuki, Yusuke
Yamamoto, Keiichi
Kitahara, Yuzuru
Suzuki, Yasuhiko
Abstract
Studies have been made extensively, and such an expression vector can be successfully constructed that enables the high-level production of a protein derived from a foreign gene in a mammal host cell. The expression vector comprises a gene cassette which contains a translation-impairing dihydrofolate reductase gene cistron and a cloning site into which a foreign gene is to be integrated, wherein codons in the translation-impairing dihydrofolate reductase gene cistron are altered to those which have been used in mammal cells with lowest frequencies to reduce the expression level thereof, and the cloning site is located between a highly transcriptionally active promoter and a highly stable polyadenylation signal.
NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (Japan)
FUSO PHARMACEUTICAL INDUSTRIES, LTD. (Japan)
Inventor
Suzuki, Yusuke
Tahara, Hiroshi
Yamamoto, Keiichi
Kitahara, Yuzuru
Suzuki, Yasuhiko
Abstract
Disclosed is a collagen gene construct which can be easily refined and which maintains a triple helix structure equivalent to that of natural collagen while having a low molecular weight. Specifically, because CR-D, which is a signal peptide, has a sugar chain recognition region, one-step refining is enabled by means of affinity refinement, and by substituting a portion of a human collagen structural gene for the collagen-like structural gene part of MBL, a low molecular weight collagen which maintains a triple helix structure with high purity and in a large amount and which has thermal stability can be obtained.
Disclosed is a composition for promoting the secretion of a tear, which can be used safely and effectively in tear secretion promotion therapies rather than conventional therapies for supplementing a tear component, and can exhibit its effect for a long period. Specifically disclosed are: a composition for promoting the secretion of a tear, which is characterized by comprising a peptide derivative represented by formula (I); and a contact lens retaining and/or containing the composition.
NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (Japan)
FUSO PHARMACEUTICAL INDUSTRIES, LTD. (Japan)
Inventor
Suzuki, Yasuhiko
Yamamoto, Keiichi
Tahara, Hiroshi
Suzuki, Yusuke
Abstract
The present inventors successfully constructed an expression vector which comprises a gene cassette containing a drug-resistant gene cistron with reduced expression and a property of impairing translation and having a cloning site for insertion of a foreign gene between a highly transcriptionally active promoter and a highly stable polyadenylation signal and is capable of producing a foreign gene-derived protein at a high level in a mammalian host cell.
C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
NATIONAL UNIVERSITY CORPORATION CHIBA UNIVERSITY (Japan)
FUSO PHARMACEUTICAL INDUSTRIES, LTD. (Japan)
Inventor
Oda, Shigeto
Sadahiro, Tomohito
Nakamura, Masataka
Tanaka, Syuichi
Tokuoka, Shogo
Otani, Hiroya
Abstract
The invention relates to a stable bicarbonate ion-containing drug solution, particularly a bicarbonate-containing drug solution for dialysis in which the stability has been improved by the presence of a phosphate ion. Further, the invention relates to a drug solution for acute blood purification, particularly a dialysate and a substitution liquid for acute blood purification to be mixed before use containing the drug solution. Still further, the invention relates to a dialysate and a substitution liquid for acute blood purification to be mixed before use in which the formation of insoluble fine particles or precipitates is prevented for a long time after mixing and with which hypokalemia and hypophosphatemia are not caused.
Multiplex PCR primers, whereby cdt genes of C. jejuni, C. coli and C. fetus can be species-specifically amplified, are constructed and the multiplex PCR is evaluated by using bacteria belonging to the genus Campylobacter and other cdt gene-positive bacteria and typical intestinal infection-causative bacteria. As a result, it has been proved that the multiplex PCR using the cdtB amplification primers as described above enable simultaneous detection of multiple kinds of bacteria belonging to the genus Campylobacter at a high specificity. According to this method, campylobacters can be identified at the species level by a single operation in the case of mixed infection of livestock animals or humans with bacteria belonging to the genus Campylobacter.
C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor
95.
DETECTION OF BACTERIUM BELONGING TO GENUS CAMPYLOBACTER WHICH TARGETS CYTOLETHAL DISTENDING TOXIN
Disclosed are: a cytolethal distending toxin (CDT) derived from C. hyointestinalis; a polynucleotide encoding the cytolethal distending toxin; and a novel method for detecting C. hyointestinalis by using cdt gene. Attention is focused on a cytolethal distending toxin (CDT) derived from a bacterium belonging to the genus Campylobacter. As a result, a cell line is found whose cdtB gene cannot be amplified by a multiplex PCR method that can detect specifically cdtA gene, cdtB gene and cdtC gene of C. jejuni, C. coli and C. fetus but can be amplified with a primer common to all of these three cell lines,by detecting cdt gene from a bacterium belonging to the genus Campylobacter isolated from a Thai enteritis patient. The analysis is made on 16S rRNA gene, and the cell line is identified as C. hyointestinalis. The full-length nucleotide sequence for cdt gene is determined by the genome walking on the upstream and the downstream from cdtB gene.
A tablet for treating postherpetic neuralgia; and a method of treating postherpetic neuralgia with the use of the tablet. The therapeutic tablet for postherpetic neuralgia is characterized by containing buprenorfin hydrochloride, having a double layer structure consisting of a quick-release layer and a sustained-release layer and being adhered to the oral mucous membrane.
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
A61P 25/04 - Centrally acting analgesics, e.g. opioids
C07D 489/02 - Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
The invention aims at providing a process for the production of a buprenorphine pharmaceutical preparation to be applied to mouth mucosa. The process is characterized by comprising the step of preparing granules for rapid release layer containing buprenorphine hydrochloride crystals whose 90% cumulative diameter is 200&mgr;m or below, the step of preparing granules for sustained release layer containing buprenorphine hydrochloride crystals whose 90% cumulative diameter is 250&mgr;m or below, and the step of compressing both the granules into double-layer tablets.
Disclosed is a novel hCL-K1 polypeptide having a collectin activity. The polypeptide comprises contiguous 271 amino acid residues as depicted in SEQ ID NO:2 and cannot bind to maltose or N-acetylgalactosamine.
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
C12P 21/02 - Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
This invention relates to an adenovirus vector having excellent gene transfection activity on specific cell lines, particularly on hematopoietic cells. This adenovirus vector derives from the adenovirus type 35 genome by at least partial or total deletion of the E1 region therefrom. The adenovirus vector according to this invention has excellent gene transfection activity on specific cell lines, particularly on hematopoietic cells, ES cells, pluripotent stem cells, blood stem cells, and tissue stem cells.
01 - Chemical and biological materials for industrial, scientific and agricultural use
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
Industrial chemicals; chemical preparations for scientific purposes (other than for medical or veterinary use); chemical substances for analysis in laboratories (other than for medical or veterinary use). Pharmaceutical preparations; veterinary preparations; sanitary preparations; chemical reagents for medical or veterinary purposes; chemical preparations for pharmaceutical purposes; diagnostic preparations for medical purposes; diagnostic reagents. Medical apparatus and instruments; medical diagnostic apparatus for detection of bacteria in phagocyte; parts and fittings for all the aforementioned goods.
